XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Note 13 - Segment Information
 3 Months Ended
Mar. 29, 2025
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

13.   Segment Information

 

The Company follows ASC 280, “Segment Reporting,” which establishes standards for companies to report information about operating segments, geographic areas and major customers. The accounting policies of each reportable segment are the same as those described in the summary of significant accounting policies (see Note 1 to the Company’s Consolidated Financial Statements).

 

The Company reports segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Makers (“CODMs”), who were Bradley Vizi, Chief Executive Officer, and Kevin Miller, Chief Financial Officer. The Company’s CODMs are responsible for making decisions regarding the Company’s business, including resource allocations and performance assessments based on historical and future segment revenue, operating expenses, and operating income (loss) before interest and taxes.

 

The tables below summarize the results of operations and total assets by segment provided to the CODMs. Segment operating income (loss) includes selling, general, and administrative expenses directly attributable to that segment and charges for allocating corporate costs to each of the operating segments. The following tables reflect the results of the reportable segments consistent with the Company’s management system:

 

Thirteen Weeks Ended

March 29, 2025

 

Specialty

Health Care

  

Engineering

  

Life Sciences,

Data &

Solutions

  

Corporate

  

Total

 

Revenue

 $43,283  $32,142  $9,048  $-  $84,473 

Cost of services

  31,080   25,957   5,458   -   62,495 

Gross profit

  12,203   6,185   3,590   -   21,978 

Selling, general and administrative

  8,311   4,741   1,919   -   14,971 

Depreciation and amortization of

property and equipment

  160   212   52   -   424 

Amortization of acquired

intangible assets

  -   -   -   -   - 

Operating income

 $3,732  $1,232  $1,619  $-  $6,583 

Total assets as of March 29, 2025

 $16,121  $47,485  $44,206  $13,180  $120,992 

Property and equipment acquired

 $35  $66  $54  $272  $427 

 

 

 

Thirteen Weeks Ended

March 30, 2024

 

Specialty

Health Care

  

Engineering

  

Life Sciences,

Data &

Solutions

  

Corporate

  

Total

 

Revenue

 $38,182  $23,505  $10,252  $-  $71,939 

Cost of services

  27,108   18,003   6,461   -   51,572 

Gross profit

  11,074   5,502   3,791   -   20,367 

Selling, general and administrative

  7,490   4,173   2,536   -   14,199 

Depreciation and amortization of

property and equipment

  104   145   38   -   287 

Amortization of acquired

intangible assets

  -   -   45   -   45 

Operating income

 $3,480  $1,184  $1,172  $-  $5,836 

Total assets as of March 30, 2024

 $43,666  $50,579  $18,411  $7,827  $120,483 

Property and equipment acquired

 $107  $199  $14  $349  $669 

 

The Company derives a majority of its revenue from offices in the United States. Revenues reported for each operating segment are all from external customers. The Company is domiciled in the United States and its segments operate in the United States, Canada, Puerto Rico and Europe. Revenue by geographic area for the thirteen weeks ended March 29, 2025 and March 30, 2024 was as follows:

 

  

Thirteen Weeks Ended

 
  

March 29,

2025

  

March 30,

2024

 

Revenue

        

United States

 $78,838  $66,851 

Canada

  1,916   1,469 

Puerto Rico

  1,607   2,001 

Europe

  2,112   1,618 

Philippines

  -   - 
  $84,473  $71,939 

 

Total assets by geographic area as of the reported periods were as follows:

 

  

March 29,

2025

  

December 28,

2024

 

Total assets

        

United States

 $113,367  $123,905 

Canada

  1,024   1,423 

Puerto Rico

  3,149   3,286 

Europe

  3,256   3,408 

Philippines

  196   55 
  $120,992  $132,077